{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:52:54Z","timestamp":1765828374093,"version":"3.40.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.soncn.2024.151614","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T13:08:12Z","timestamp":1709557692000},"page":"151614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-9929","authenticated-orcid":false,"given":"Lucy","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla M.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Difilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salimah H.","family":"Meghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.soncn.2024.151614_bib0001","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.soncn.2024.151614_bib0002","unstructured":"Institute KC. CAR T-Cell Therapy for Cancer. Oregon Health Sciences University"},{"issue":"5","key":"10.1016\/j.soncn.2024.151614_bib0003","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2024.151614_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy vs autologous and allogeneic stem cell transplant","author":"Sidana","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.soncn.2024.151614_bib0005","article-title":"Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with CAR T-cell therapy: a qualitative study","author":"Cheng","year":"2021","journal-title":"Oncol Ther"},{"issue":"11","key":"10.1016\/j.soncn.2024.151614_bib0006","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.soncn.2024.151614_bib0007","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.soncn.2024.151614_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/nur.21768","article-title":"Characteristics of qualitative descriptive studies: a systematic review","volume":"40","author":"Kim","year":"2017","journal-title":"Res Nurs Health"},{"key":"10.1016\/j.soncn.2024.151614_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.soncn.2024.151614_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1609406917733847","article-title":"Thematic analysis: striving to meet the trustworthiness criteria","volume":"16","author":"Nowell","year":"2017","journal-title":"Int J Qual Methods"},{"year":"1985","series-title":"Naturalistic Inquiry","author":"Lincoln","key":"10.1016\/j.soncn.2024.151614_bib0011"},{"issue":"8","key":"10.1016\/j.soncn.2024.151614_bib0012","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2024.151614_bib0013","article-title":"Intercoder reliability in qualitative research: debates and practical guidelines","volume":"19","author":"O'Connor","year":"2020","journal-title":"Int J Qual Methods"},{"key":"10.1016\/j.soncn.2024.151614_bib0014","unstructured":"NVivo (released in March 2020). 2020."},{"issue":"6","key":"10.1016\/j.soncn.2024.151614_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151216","article-title":"The unique symptom burden of patients receiving CAR T-cell therapy","volume":"37","author":"Whisenant","year":"2021","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.soncn.2024.151614_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","author":"Wang","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.soncn.2024.151614_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.004","article-title":"Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T","author":"Akinola","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.soncn.2024.151614_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2024.151614_bib0019","series-title":"Transpl Cell Ther","article-title":"Change in patients perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma","author":"Barata","year":"2021"},{"issue":"5","key":"10.1016\/j.soncn.2024.151614_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-023-07763-x","article-title":"Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study","volume":"31","author":"Mao","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2024.151614_bib0021","article-title":"A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: recommendations for service development and implications for palliative care teams","author":"Stenson","year":"2022","journal-title":"Palliat Med"},{"key":"10.1016\/j.soncn.2024.151614_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-022-01240-0","article-title":"Rehabilitation needs for patients undergoing CAR T-cell therapy","author":"Obaisi","year":"2022","journal-title":"Curr Oncol Rep"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:36:06Z","timestamp":1729229766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0749208124000536"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151614","relation":{},"ISSN":["0749-2081"],"issn-type":[{"type":"print","value":"0749-2081"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151614"}}